{"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year.","id":"BG000","title":"Pembrolizumab"},{"description":"Participants received placebo, IV, every 3 weeks, for one year.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.5","value":"64.1"},{"groupId":"BG001","spread":"8.4","value":"64.5"},{"groupId":"BG002","spread":"8.4","value":"64.3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"373"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"401"},{"groupId":"BG001","value":"403"},{"groupId":"BG002","value":"804"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"214"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"450"},{"groupId":"BG001","value":"455"},{"groupId":"BG002","value":"905"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"41"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"172"}],"title":"Stage IB"},{"measurements":[{"groupId":"BG000","value":"330"},{"groupId":"BG001","value":"338"},{"groupId":"BG002","value":"668"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"160"},{"groupId":"BG002","value":"335"}],"title":"Stage IIIA"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Stage IV"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were classified per American Joint Committee on Cancer Manual Edition 7th (AJCC V7) based on TNM classification where T refers to size and extent of primary tumor and if it invaded nearby tissue, N refers to location of nearby lymph nodes that have cancer and M refers to distant metastasis (spread of cancer to other parts). In stages I, II and III the cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues. In stage IV, the cancer has spread to distant parts of the body. Higher numbers mean the cancer is more advanced.","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Stage at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"233"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"465"}],"title":"TPS <1%"},{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"379"}],"title":"TPS 1-49%"},{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"333"}],"title":"TPS ≥50%"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from a biopsy. Participants with a tumor proportion score (TPS) were classified as follows: \\<1% = PD-L1 negative, 1-49% = PD-L1 weakly positive; and ≥50% = PD-L1 strongly positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Status at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"506"},{"groupId":"BG001","value":"504"},{"groupId":"BG002","value":"1010"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"167"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were classified per receiving of standard adjuvant chemotherapy at baseline: Yes or No.","paramType":"COUNT_OF_PARTICIPANTS","title":"Adjuvant Chemotherapy at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"303"},{"groupId":"BG001","value":"301"},{"groupId":"BG002","value":"604"}],"title":"Western Europe"},{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"229"}],"title":"Eastern Europe"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"133"}],"title":"Rest of the World"},{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"211"}],"title":"Asia"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were classified based on their geographic region as those from: Western Europe, Easter Europe, Asia and Rest of the world.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"192"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"416"}],"title":"Squamous"},{"measurements":[{"groupId":"BG000","value":"398"},{"groupId":"BG001","value":"363"},{"groupId":"BG002","value":"761"}],"title":"Non-squamous"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"153"}],"title":"Never smoker"},{"measurements":[{"groupId":"BG000","value":"428"},{"groupId":"BG001","value":"431"},{"groupId":"BG002","value":"859"}],"title":"Former smoker"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"165"}],"title":"Current smoker"}],"denoms":[{"counts":[{"groupId":"BG000","value":"590"},{"groupId":"BG001","value":"587"},{"groupId":"BG002","value":"1177"}],"units":"Participants"}]}],"description":"Participants were classified per centers of disease control and prevention (CDC) as: Never smoker (smoked fewer than 100 cigarettes in his/her lifetime), former smoker (smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview. and current smoker (smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes) at baseline.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking status","unitOfMeasure":"Participants"}],"populationDescription":"All randomized participants. One participant randomized to the study in error did not provide informed consent and was not included. No data was collected on this participant."}